New Jersey
PSYCHEDELIC REGULATIONS FOR BUSINESSES IN NEW JERSEY
New Jersey does not have a legal commercial market for psychedelics. Therefore, the state does not license psychedelic manufacturers, retailers, service centers, or facilitators.
Psilocybin, psilocin, DMT, mescaline, ibogaine, LSD, and similar substances remain controlled substances. Their possession, production, and distribution can lead to criminal penalties.
However, New Jersey treats possession of small amounts of psilocybin differently from most other psychedelic offenses. In 2021, the state reduced the penalty for possessing one ounce or less.
That change did not legalize psilocybin. It also did not create a regulated business market.
Can Psychedelic Businesses Operate in New Jersey?
No. New Jersey has not created a licensing system for commercial psychedelic activity.
Businesses cannot legally manufacture or sell psilocybin products. They also cannot operate supervised psilocybin service centers under current state law.
In addition, New Jersey does not authorize psychedelic retreats or commercial facilitation services. Calling a service educational, spiritual, or therapeutic does not automatically make it legal.
Businesses that handle controlled substances without proper authorization may face criminal charges. Owners may also face licensing, banking, property, and insurance consequences.
Psilocybin Possession Penalties
New Jersey enacted P.L. 2021, Chapter 9 on February 4, 2021. The law changed the penalty for possessing one ounce or less of psilocybin.
That offense is now a disorderly persons offense. It may carry up to six months in jail, a fine of up to $1,000, or both.
Therefore, New Jersey did not fully decriminalize psilocybin. Instead, it reduced the offense from a third-degree crime to a lower-level criminal offense.
Possession of larger amounts may lead to more serious charges. Distribution, manufacturing, and possession with intent to distribute also remain illegal.
Other psychedelic substances do not receive this reduced psilocybin penalty. As a result, possession of DMT, LSD, mescaline, ibogaine, or similar substances may bring felony-level charges.
Cultivation and Manufacturing Restrictions
New Jersey does not allow people or businesses to cultivate psilocybin mushrooms for commercial use.
Likewise, businesses cannot extract, process, package, or manufacture psychedelic products. These activities remain illegal without specific research authorization.
The state’s cannabis laws do not apply to psychedelics. Therefore, a cannabis license does not authorize a business to handle psilocybin or another psychedelic substance.
Hemp and wellness licenses also provide no protection for psychedelic activity.
Psychedelic Therapy and Facilitation
New Jersey does not currently license psychedelic-assisted therapy.
Healthcare providers cannot prescribe psilocybin, DMT, LSD, or other unapproved psychedelics under ordinary medical practice. Therapists also cannot provide these substances to clients outside authorized research.
However, licensed professionals may discuss published research and general treatment developments. They must still follow professional standards and controlled-substance laws.
Businesses should be cautious when using terms such as “psychedelic therapy” or “psilocybin treatment.” Marketing can create legal risk when the advertised service includes unlawful access or administration.
Research and Clinical Trials
Authorized research remains the main legal pathway for working with psychedelic substances in New Jersey.
However, research institutions must follow strict federal requirements. Schedule I researchers generally need registration from the Drug Enforcement Administration.
Drug developers may also need Food and Drug Administration approval for a clinical investigation. In addition, researchers must follow institutional review and patient-protection requirements.
The FDA issued final guidance for psychedelic drug clinical investigations in July 2026. The guidance addresses several issues unique to psychedelic drug trials.
Still, research approval does not authorize general commercial sales. It only covers the activities allowed under the approved research protocol.
Proposed Psilocybin Service Center Legislation
New Jersey lawmakers have considered a regulated psilocybin services model.
During the 2024 legislative session, lawmakers introduced Senate Bill S2283. The proposal was called the Psilocybin Behavioral Health Access and Services Act.
The bill proposed a supervised system rather than a retail market. Under that model, patients would consume psilocybin at licensed service centers.
The proposal did not become law during that legislative session. However, lawmakers returned to the issue in 2026.
Senate Bill S3148 was prefiled for the 2026 session. As of September 4, 2026, the bill remained a proposal and had not become law.
If enacted, S3148 would create several license categories:
- Psilocybin product manufacturers
- Psilocybin service center operators
- Psilocybin testing laboratories
- Psilocybin service facilitators
- Psilocybin workers
The bill would place the program under the New Jersey Department of Health. It would also create a Psilocybin Behavioral Health Access and Services Advisory Board.
How the Proposed Program Would Work
S3148 would create an 18-month program development period. Afterward, the Department of Health would regulate psilocybin manufacturing, testing, transportation, and services.
The department would begin accepting license applications within 24 months of enactment.
However, the proposal would not create traditional psychedelic dispensaries. Patients could not buy psilocybin for unrestricted use at home.
Instead, psilocybin would be consumed at a licensed service center. A trained facilitator would supervise each administration session.
Patients would also need to be at least 21 years old. In addition, they would need a written certificate from an authorized healthcare practitioner.
The proposed process would include:
- A preparation session
- A supervised administration session
- A required integration session
- Health and safety screening
- Product testing and tracking
- Facilitator licensing and training
Still, none of these licenses are currently available. Businesses cannot begin operating based on the proposed bill.
Business Planning and Compliance
Businesses interested in New Jersey’s potential psychedelic market should monitor S3148 and related proposals.
However, they should avoid selling or handling controlled substances before legislation takes effect. Forming a company does not authorize psychedelic activity.
Future operators may eventually need to prepare for:
- State licensing
- Municipal zoning approval
- Product testing
- Inventory tracking
- Facility security
- Employee permits
- Clinical oversight
- Insurance requirements
- Advertising restrictions
Payment processing would also require careful review. Banks and payment providers generally require proof that every product and service is legal.
Businesses operating in lawful research, healthcare, wellness, or adjacent markets may contact PayRio to discuss available payment options. Services depend on the business model, products, licensing, and completed underwriting.
PSYCHEDELIC LEGALIZATION HISTORY IN NEW JERSEY
New Jersey prohibited psychedelics for decades under its controlled-substance laws.
In 2021, the state reduced the penalty for possessing one ounce or less of psilocybin. However, the conduct remained a criminal offense.
Lawmakers introduced S2283 in 2024. The bill proposed licensed psilocybin manufacturing, testing, service centers, and facilitators.
Although S2283 did not become law, lawmakers reintroduced the core proposal as S3148 for the 2026 session.
The current bill focuses on behavioral health and supervised use. Therefore, it differs from a recreational retail or dispensary model.
PSYCHEDELIC LEGALIZATION STATUS IN NEW JERSEY
Current status: Illegal, with a reduced penalty for limited psilocybin possession
New Jersey law currently:
- Prohibits commercial psychedelic manufacturing and sales
- Does not license psilocybin service centers
- Does not authorize psychedelic-assisted therapy outside approved research
- Treats possession of one ounce or less of psilocybin as a disorderly persons offense
- Allows properly authorized clinical and academic research
- Continues to prohibit home cultivation and commercial facilitation
New Jersey may eventually adopt a supervised psilocybin program. However, S3148 must pass the Legislature and receive the governor’s approval before that can happen.
Until then, no legal commercial psychedelic market exists in New Jersey.
LAST UPDATED 9/4/2026 – Laws can change frequently, so businesses should confirm current requirements with state regulators and qualified legal counsel.